Developmental Therapeutics Clinic

The newest treatments for advanced cancers. 

Clinic Information
The Development Therapeutics Clinic will be housed at the M Health Fairview Clinics and Surgery Center, 2nd Floor, on Wednesday mornings from 8 am to 12 pm. Referring physicians and patients can get more information by contacting the Masonic Cancer Center Nurse Information line at or call the M Health Fairview Cancer Care line at 855-486-7226.

The Developmental Therapeutics Clinic, located at the M Health Fairview Clinics and Surgery Center, offers Phase 1 cancer clinical trials. This is a partnership between M Health Fairview, the University of Minnesota Medical School Division of Hematology, Oncology And Transplantation, the Division of Gynecologic Oncology, and the Masonic Cancer Center, University of Minnesota.

Mission Statement
To create hope for patients, generate opportunities for faculty, and to construct a forum for researchers to conceptualize cutting edge bench-to-bedside research.

Please send referrals to and/or to DTC intake pool "P DTC TEAM".
You can also call: 855-486-7226, or send referrals via fax: 612-676-6416.

Developmental Therapeutics Clinic Oncologists

Dr. Patel
Manish Patel, DO

Associate Professor of Medicine
Division of Hematology, Oncology and Transplantation

Dr. Patel received a BS in Molecular Biology from Vanderbilt University in 1996. He then attended Kirksville College of Osteopathic Medicine, receiving a Doctor of Osteopathy degree in 2001. Dr. Patel then pursued residency in Internal Medicine at McGaw Medical Center of Northwestern University. He followed this with a clinical research fellowship at Winthrop University Hospital (Mineola, NY) from 2004-2006. In 2006 he joined the Hematology, Oncology and Transplantation fellowship at the University of Minnesota and in July 2010 became a faculty member of the Division. Dr. Patel is a physician-scientist researching oncolytic virus for lung cancer. In 2019, Dr. Patel became the associate program director for the hematology, oncology, and transplantation fellowship program. He also leads the experimental therapeutics phase I clinical program at the University of Minnesota.

Dr. Teoh
Deanna Teoh, MD, FACS, FACOG

Assistant Professor
Department of Obstetrics, Gynecology and Women's Health (OBGYN)

Dr. Teoh is a gynecologic oncologist in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology. She graduated summa cum laude from Macalester College (2000) with a Bachelor’s degree in music. She received her M.D. degree from the Medical College of Wisconsin (2004). She completed residency training in Obstetrics & Gynecology at the University of California San Francisco (2008) and then subsequently completed a subspecialty fellowship in Gynecologic Oncology at Duke University (2010). Dr. Teoh joined the Gynecologic Oncology faculty of the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota in 2011

Dr. Musibay Evidio
Evidio Domingo-Musibay, MD

Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation

Dr. Domingo-Musibay is an Assistant Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota and member of the Masonic Cancer Center. My clinical and translational research efforts focus on immunologic, cellular, and viral and gene therapy treatments for solid tumors. I am particularly interested in defining optimal immunotherapy sequencing strategies and mechanisms of resistance to standard immunotherapy agents, and identification of promising in situ vaccination and adoptive cell therapy based immunotherapy treatments. My graduate and post-graduate training in virology, immunology, and hematology/oncology has equipped me to interface between basic science discovery and clinical translation of novel therapies for cancer patients.

Dr. Fujioka
Naomi Fujioka, MD

Associate Professor
Division of Hematology, Oncology and Transplantation

Dr. Fujioka is a Medical Oncologist specializing in thoracic and head/neck malignancies. Her research is focused on developing food-based chemoprevention against tobacco and environmental carcinogens. Dr. Fujioka also acts as site Principal Investigator for cancer therapy clinical trials. She joined the faculty in 2011 after completing all of her training at the University of Minnesota.

Available Trials

1) 2020IS145 Enfortumab Vedotin An Open-label, Multicohort, Phase 2 Study to Evaluate Enfortuamab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

2) 2020IS097 Phase 2 Tumor-agnostic Precision Immunooncology and Somatic Targeting Rational for you (TAPISTRY) 

3) 2020IS022 MRTX849 A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

4) 2020IS186 A Phase 1b/2, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 In Combination With Cetuximab As A Salvage Regimen For Solid Tumors

5) 2020IS202 A Phase 1, Open Label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors

6) 2021IS084 A Phase 1, First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 Inhibitor Monoclonal Antibody JTX-8064, As Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies Jounce

7) 2021IS114: A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients with Locally Advanced or Metastatic Solid Tumours

8) 2021LS143: A Phase I Study of HCW9218, a Bifunctional TGF-B; Antagonist/IL-15 Protein Complex, in Select Advanced Solid Tumors After Failing at Least Two Prior Therapies